Under ASA monotherapy, the difference between PED with and without Shield Technology fell just short of significance ( figure 1 E; p=0.084; PED: 1.6±1.1×10 9 platelets; PED+Shield: 0.52±0.26×10 9 platelets).
← all excerpts
Thrombogenicity of flow diverters in an ex vivo shunt model: effect of phosphorylcholine surface modification.
2
0.0840
0.0840
The sentences
Thus, while statistical significance was achieved only in ASA trials, FRED showed a trend towards greater platelet accumulation in the absence of clopidogrel.